A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
for Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Drug: Nadofaragene Firadenovec
Sites in New Haven +38 more locations
Sponsor: Ferring Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06545955·Phase 3·Recruiting·Listed Aug 2024